Antifibrotic effect of interferons? The hepatologist point of view;Les interférons ont-ils une action antifibrosante ? Le point de vue de l'hépatologue

Revue de Medecine Interne

Volumn 23, Issue SUPPL. 4, 2002, Pages

  Poynard, T ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cirrhosis; Fibrosis; HCV; Interferon; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIFIBROTIC AGENT; INTERFERON; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NECROSIS; MONOTHERAPY; NONHUMAN; REVIEW;

EID: 17344382197     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00668-9     Document Type: Article

References (20)

1. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
2. Friedman SL. The cellular basis of hepatic fibrosis: Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35.
3. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994;20(1):15-20.
4. Poynard T, Ratziu V, Benhamou Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: Detection and significance. Semin Liver Dis 2000;20:47-55.
5. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M, et al. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 1999;116:378-86.
6. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
7. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
8. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:543-8.
9. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-75.
10. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial. J Viral Hepat 2002;9:128-33.
11. Pilette C, Fort J, Riffiet H, Cales P. Effets antifibrosants des interférons. Gastroentérol Clin Biol 1997;21:466-71.
12. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update. J Viral Hepat 2001;8:48-62.
13. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-99.
14. Dufour JF, DeLellis R, Kaplan MM. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci 1998;43:2573-6.
15. Shiffman ML, Hofinann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
16. Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, et al. Reinforced regimen of interferon alpha 2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: A multicenter randomized trial. J Hepatol 1998;29:224-32.
17. Castilla A, Priesto J, Fausto N. Transforming growth factors beta-1 and alpha in chronic liver disease: Effects of interferon alpha therapy. N Engl J Med 1991;324:933-40.
18. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alpha 2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.
19. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay L, Goodman Z, et al. Impact of pegylated interferon alpha 2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
20. Pol S, Serfaty L, Lagneau JL, Brechot C. Reversibility of hepatitis C virus related cirrhosis. Hepatology 2000;32:361 [abstract].